

as 45  
32  
Add B3

(New) An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to an amino acid sequence of SEQ ID NO:32.

### REMARKS

Upon entry of the foregoing amendments, claims 1, 2, 4, 29, 32, 44, and 45 are under consideration.

Support for the amendments to claims 1, 2, 4, 29, and 32 may be found in the claims as originally filed. Thus, these amendments add no new matter.

Applicants make these amendments solely in response to the restriction requirement to claim the elected invention.

### CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Cynthia Kozakiewicz, Reg. No. 42,764  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

DATED: July 8, 2002

*Version With Markings to Show Changes*

1. (Amended) An isolated polypeptide comprising the [an amino acid sequence selected from the group consisting of:]
  - [a] a] mature form of [the] an amino acid sequence [given by] of SEQ ID NO:32. [2n, wherein n is an integer between 1-16;]
  - [b] a variant of a mature form of the amino acid sequence given by SEQ ID NO:2n, wherein n is an integer between 1-16 , wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;]
  - [c] the amino acid sequence given by SEQ ID NO:2n, wherein n is an integer between 1-16;]
  - [d] a variant of the amino acid sequence given by SEQ ID NO:2n, wherein n is an integer between 1-16 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and]
  - [e] a fragment of any of a) through d).]
2. (Amended) The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence given by SEQ ID NO:32[2n, wherein n is an integer between 1-16].
4. (Amended) [The] An isolated polypeptide [of claim 1 that is a variant polypeptide described therein], wherein [any amino acid specified in the chosen sequence is changed to provide] the polypeptide comprises an amino acid sequence comprising one or more [a] conservative substitutions [.] in the amino acid sequence [selected from the group consisting] of SEQ ID NO:32[2n, wherein n is an integer between 1 and 16].
29. (Amended) A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
32. (Amended) A kit comprising in one or more containers, the pharmaceutical composition of claim 29.